Pharmacodynamics and Uses of Phenobarbital
Phenobarbital (Phenobarbitalum) is classified as a long-acting barbiturate. The drug exhibits prominent antiepileptic, hypnotic, and sedative effects.
In modern clinical practice, its use is strictly differentiated:
- Antiepileptic agent: This is the primary and most justified indication for prescribing phenobarbital.
- Hypnotic agent: In this capacity, the drug is used very restrictively due to pronounced adverse effects.
- Sedative agent: Phenobarbital is frequently used in low doses as a component of well-known combination drugs (e.g., Valocordin drops), where it provides a calming effect.
Pharmacokinetics and Hepatic Effects
A distinctive feature of phenobarbital is its slow elimination from the body. The clinical effect after ingestion lasts for about 8 hours; however, delayed elimination creates a high risk of accumulation—a dangerous buildup of the active substance in the body with regular intake.
A critically important aspect of phenobarbital pharmacokinetics is its effect on the hepatobiliary system. It acts as a potent inducer of hepatic microsomal enzymes. This leads to two major consequences:
- The metabolism of other concurrently administered drugs is accelerated, which can reduce their efficacy.
- The phenomenon of autoinduction occurs—the drug accelerates its own metabolism with prolonged use.
Adverse Effects of Barbiturates
The use of phenobarbital is associated with several serious adverse reactions. Like all representatives of the barbiturate group, it severely disrupts the physiological sleep architecture.
Of particular note is the hangover (zmiva/aftereffect) syndrome. The morning after taking the drug, the patient does not feel rested; instead, they experience:
- Generalized central nervous system depression and somnolence.
- A feeling of severe malaise or "hangover-like" sluggishness.
- Various movement disorders.
Furthermore, systemic reactions such as arterial hypotension and allergic manifestations (e.g., skin rashes) are possible. Repeated and prolonged use inevitably leads to tolerance (habituation requiring dose escalation) and severe drug dependence.
Characteristics of Cyclobarbital
Cyclobarbital is a short- to intermediate-acting barbiturate. Its clinical effect lasts approximately 5–6 hours, and the elimination half-life ($t_{1/2}$) ranges from 20 to 25 hours.
Compared to phenobarbital, cyclobarbital has an important advantage: the hangover (aftereffect) syndrome is significantly less pronounced. Historically, this drug was widely used in medicine before the introduction of safer benzodiazepines. Today, it is rarely used in pure form, but it finds modern application as a component of the combination hypnotic drug Reladorm, where its action is complemented by the tranquilizer diazepam.